1036069-26-7
1036069-26-7
Chemical Structure
RETRA
- CAS No.: 1036069-26-7
- Formula:C11H11NO3S2
- Molecular Weight:269.34
IUPAC Name: 2-((4,5-dihydrothiazol-2-yl)thio)-1-(3,4-dihydroxyphenyl)ethan-1-one
InChIKey: OHNNJGHRUIGGBO-UHFFFAOYSA-N
SMILES: OC1=CC=C(C(CSC2=NCCS2)=O)C=C1O
Biological Activity: RETRA is a RIPK1/RIPK3/MLKL and p73 activator. RETRA mediates plasma membrane disruption, induces ROS accumulation, triggers early mitochondrial hyperpolarization, and synergistically drives necroptosis. RETRA inhibits cancer cells carrying mutant p53 via a p73-dependent salvage pathway. RETRA can be used in research related to cervical cancer and cancers with mutant p53[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RETRA | 98.83% | RETRA is a RIPK1/RIPK3/MLKL and p73 activator. RETRA mediates plasma membrane disruption, induces ROS accumulation, triggers early mitochondrial hyperpolarization, and synergistically drives necroptosis. RETRA inhibits cancer cells carrying mutant p53 via a p73-dependent salvage pathway. RETRA can be used in research related to cervical cancer and cancers with mutant p53. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mohanty S, et al. RETRA induces necroptosis in cervical cancer cells through RIPK1, RIPK3, MLKL and increased ROS production. Eur J Pharmacol. 2022;920:174840. [Content Brief]
- [2]. Kravchenko JE, et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci U S A. 2008;105(17):6302-6307. [Content Brief]
